GFA
PLRX icon

Gallagher Fiduciary Advisors’s Pliant Therapeutics PLRX Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,434
Closed -$15.4K – 339
2025
Q1 		$15.4K Sell
11,434
-455
-4% -$2.76K ﹤0.01% 303
2024
Q4 		$157K Buy
11,889
+1,880
+19% +$25.7K 0.03% 287
2024
Q3 		$112K Buy
+10,009
New +$125K 0.02% 269

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Gallagher Fiduciary Advisors's PLRX Position: Q2 2025 in Review

Gallagher Fiduciary Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 11,434 shares — an estimated $15.4K sold.

Gallagher Fiduciary Advisors first reported a position in PLRX in Q3 2024 and held it in 3 quarters. The position peaked at $157K in Q4 2024. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • Gallagher Fiduciary Advisors reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Gallagher Fiduciary Advisors sold 11,434 Pliant Therapeutics shares in Q2 2025, an estimated $15.4K.
  • Gallagher Fiduciary Advisors first reported a position in Pliant Therapeutics in Q3 2024 and held it in 3 quarters.
  • Gallagher Fiduciary Advisors's Pliant Therapeutics position peaked at $157K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Gallagher Fiduciary Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.